Story perspectives

FDA Advisory Panel Votes 8-6 to Allow Unapproved Peptides

7/25/2026

Center

FDA Panel Approves

The FDA Pharmacy Compounding Advisory Committee met in Silver Spring, Maryland on July 23-24, 2026 and voted to allow compounding pharmacies to produce several unapproved peptides.
Many advisory members have peptide industry ties, and Secretary Robert F. Kennedy Jr. is pushing broader access despite limited safety evidence.
Panel voted 8-6 for BPC-157, KPV, TB-500 and 7-5 for MOTS-c.
FDA staff recommended against all seven peptides, citing insufficient safety and efficacy data.

Left

FDA Panel Approves

FDA’s Pharmacy Compounding Advisory Committee met in Silver Spring, Maryland on July 23-24, 2026 and voted to recommend allowing compounding pharmacies to produce unapproved peptides.
Critics warned vote could expose patients to safety risks while wellness influencers and telehealth firms touted moving users from overseas markets to U.S. pharmacies.
Four FDA scientists warned the peptides lack robust human safety data and are highly formulation-sensitive.
The committee’s 8-6 vote included one abstention.

History

Historical Context

After a series of high-profile deaths—including Steve Bechler in 2003 and 155 fatalities linked to ephedra—FDA Commissioner David Kessler pushed a 2004 ban on ephedrine-alkaloid supplements, backed by the American Heart Association and Senator Orrin Hatch. That precedent frames today’s FDA advisory committee vote on peptide drugs, where figures such as Robert F. Kennedy Jr. press for broader access.

1 of 3

FDA Panel Approves

The FDA Pharmacy Compounding Advisory Committee met in Silver Spring, Maryland on July 23-24, 2026 and voted to allow compounding pharmacies to produce several unapproved peptides.
Many advisory members have peptide industry ties, and Secretary Robert F. Kennedy Jr. is pushing broader access despite limited safety evidence.
Panel voted 8-6 for BPC-157, KPV, TB-500 and 7-5 for MOTS-c.
FDA staff recommended against all seven peptides, citing insufficient safety and efficacy data.

1 / 3